Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00730457 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine

A Phase 1 study of Influenza, sponsored by VaxInnate Corporation.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target
1
Study location

NCT00730457 is a Phase 1 study of Influenza that has completed, run by VaxInnate Corporation. The registered enrollment target is 56 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00730457, a Phase 1 study of Influenza, has completed, sponsored by VaxInnate Corporation.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

Is VAX125 safe at doses ranging from 0.1 to 8 ug when delivered i.m. in a single dose regimen Is VAX125 able to induce a post-vaccination serum HAI antibody response in healthy adults against the influenza A virus H1 HA.

Conditions Studied

Influenza

Interventions

  • BIOLOGICAL VAX125

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2008-07
Est. Completion 2009-06
Phase Phase 1

Sponsor

VaxInnate Corporation

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00730457

The ClinicalTrials.gov registry entry for NCT00730457 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is VaxInnate Corporation, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which VAX125 is the first listed.

NCT00730457 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00730457 about?

NCT00730457 is a clinical study titled "Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine". Is VAX125 safe at doses ranging from 0.1 to 8 ug when delivered i.m. in a single dose regimen Is VAX125 able to induce a post-vaccination serum HAI antibody response in healthy adults against the influenza A virus H1 HA.

What is the current status of trial NCT00730457?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2008-07. Estimated completion is 2009-06.

What conditions does trial NCT00730457 study?

This clinical trial studies the following conditions: Influenza.

What interventions are being tested in trial NCT00730457?

The interventions under investigation include: VAX125 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00730457?

This trial is sponsored by VaxInnate Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00730457 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Influenza

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Influenza

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.